Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Contravir Pharmaceut (CTRV)

0.25403 0.007 (2.85%)

05-23 15:47

Open:

0.2625

Pre. Close:

0.247

High:

0.2625

Low:

0.2353

Volume:

246,017

Market Cap:

22M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

0.26 - 0.261

0.261 - 0.263

Low:

0.237 - 0.238

0.238 - 0.24

Close:

0.248 - 0.25

0.25 - 0.252

Technical analysis  (as of: 2018-05-23 4:26:17 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 0.31     One year: 0.34

Support:

Support1: 0.22    Support2: 0.19

Resistance:

Resistance1: 0.27    Resistance2: 0.29

Pivot:

0.26

Moving Averages:

MA(5): 0.26     MA(20): 0.26

MA(100): 0.27     MA(250): 0.44

MACD:

MACD(12,26):     Signal(12,26,9):

%K %D:

%K(14,3): 33.16     %D(3): 39.99

RSI:

RSI(14): 48.11

52-Week:

High: 0.825  Low: 0.205  Change(%): -61.8

Average Vol(K):

3-Month: 75680  10-Days 34390

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CTRV has closed above bottom band by 36.0%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to CTRV's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-05-01T12:34:14-04:00
ContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential

2018-02-24T08:00:00-05:00
Your Daily Pharma Scoop: Clovis Oncology Gets A Boost, Mesoblast Positive Data, Kadmon's Updated Results

2018-02-22T12:01:18-05:00
ContraVir's TXL an Orphan Drug in U.S. for pediatric HBV infection; shares up 7%

2018-02-14T08:00:00-05:00
Your Daily Pharma Scoop: Akebia Update, Rexahn Data, Concert Commences Enrollment

2018-02-12T13:14:17-05:00
ContraVir to use abbreviated regulatory path for HBV candidate TXL; shares up 26%

2018-02-09T12:37:01-05:00
Key healthcare events next week (continued)

2018-02-07T08:00:00-05:00
Your Daily Pharma Scoop: Nabriva Pullback, GW Pharmaceuticals Makes Progress, ContraVir Announces Promising Results

2018-02-06T06:57:51-05:00
ContraVir's HBV candidate TXL well-tolerated in patients with renal impairment

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

NA

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

84.95

Shares Float (M)

84.00

% Held by Insiders

1.10

% Held by Institutions

6.50

Shares Short (K)

3782

Shares Short Prior Month (K)

3950

Stock Financials

EPS

-0.320

EPS Est. Current Year

-0.370

EPS Est. Next Year

-0.370

EPS Est. Next Quarter

-0.080

Forward EPS

1.#IO

Book Value (p.s.)

8.930

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

-116.2

Return on Equity (ttm)

-491.2

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.188

Qtrly Earnings Growth

Operating Cash Flow (M)

-16.42

Levered Free Cash Flow (M)

atoplab.com

Valuation

P/E

-0.79

P/E Growth Ratio

0.03

P/BV

0.03

P/S

P/CF

-1.31

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.